Lenvatinib dosing is indication-specific. The following table summarizes current U.S. LENVIMA prescribing information and should not be interpreted as an individualized prescription.
| Indication | Current U.S. labeled regimen |
|---|---|
| Differentiated thyroid cancer | 24 mg orally once daily |
| Advanced RCC, first line | 20 mg once daily with pembrolizumab |
| Advanced RCC after prior anti-angiogenic therapy | 18 mg once daily with everolimus 5 mg |
| Unresectable HCC, ≥60 kg | 12 mg once daily |
| Unresectable HCC, <60 kg | 8 mg once daily |
| Selected advanced endometrial carcinoma | 20 mg once daily with pembrolizumab |
Renal impairment
For severe renal impairment, current U.S. labeling provides lower recommended doses for several indications. For example, the labeled DTC dose is 14 mg daily, while the labeled RCC and endometrial-carcinoma dose is 10 mg daily in severe renal impairment.
Hepatic impairment
For severe hepatic impairment, the U.S. label recommends reduced doses for DTC, RCC and endometrial carcinoma. The specific dose depends on the indication.
Dose modification
Lenvatinib doses may be interrupted, reduced or permanently discontinued in response to adverse reactions. The appropriate modification depends on the toxicity and treatment indication.
Administration
Lenvatinib is taken orally once daily, with or without food. If a missed dose cannot be taken within 12 hours, current U.S. labeling instructs patients to skip it and take the next dose at the usual time.
Important jurisdictional limitation
The doses above are based on current U.S. labeling. Local prescribing information may differ. Patients and clinicians should use the prescribing information applicable to their jurisdiction.